Your search for major depressive disorder returned 114 results

Researchers conducted a phase 2 trial to assess the safety and efficacy of single-dose psilocybin treatment for major depressive disorder.

An umbrella review assessed the safety and efficacy of antidepressants in patients with depression and comorbid medical diseases.

Researchers investigated the all-cause risk for mortality in patients with major depressive disorder exhibiting suicidal behavior.

Review authors aimed to assess the effect of educational interventions on knowledge acquisition and health outcomes in adolescents with feeding and eating disorders.

Researchers sought to evaluate the safety of COVID-19 vaccination in pregnant and breastfeeding women with autoimmune diseases.

An eye-tracking test has identified a potential performance-based biomarker for the early diagnosis of autism spectrum disorder (ASD).

A study sought to determine the prevalence of depression and cognitive dysfunction in patients receiving TAVR for aortic stenosis and its effect on mortality.

Researchers evaluated the risk for major depressive disorder among patients with HIV infection.

Botulinum toxin injections can improve quality of life for patients across a variety of aspects of health care, including pain management, urology, dermatology, and more.

A study was conducted to determine the effect of mental health disorders on postoperative outcomes following EVAR in patients who are veterans.

Ulotaront is a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.

Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Researchers seek to evaluate whether trauma-focused therapy adjunctive to treatment as usual (TAU) leads to a greater reduction of depressive symptoms posttreatment vs TAU exclusively in patients with major depressive disorder with childhood trauma.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.

Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.

Some men have said that honest communication and community-based approaches make them more like to engage in mental health care.

Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.